(The Obesity Society) - Obesity is a chronic disease affecting over 100 million Americans. Despite its prevalence and serious health consequences, widespread insurance barriers limit access to FDA-approved GLP-1 treatments.
Fortunately, that may be changing. The Trump administration and FDA-approved GLP-1 manufacturers recently announced a partnership to expand access to these potentially life-saving medications by lowering monthly prices to $299 for cash-pay patients and covering millions of Medicare patients with a $50 monthly copay. It’s time for states—who, under the deal, can purchase FDA-approved GLP-1s on the same terms as Medicare—and private insurers to step up and do their part by covering these treatments. Otherwise, some patients may continue to turn to unsafe compounded GLP-1 knockoffs.
Keep it Clean. Please avoid obscene, vulgar, lewd,
racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another
person will not be tolerated. Be Truthful. Don't knowingly lie about anyone
or anything. Be Nice. No racism, sexism or any sort of -ism
that is degrading to another person. Be Proactive. Use the 'Report' link on
each comment to let us know of abusive posts. Share with Us. We'd love to hear eyewitness
accounts, the history behind an article.
- Obesity is a chronic disease affecting over 100 million Americans. Despite its prevalence and serious health consequences, widespread insurance barriers limit access to FDA-approved GLP-1 treatments.
(0) comments
Welcome to the discussion.
Log In
Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
PLEASE TURN OFF YOUR CAPS LOCK.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.